Moderna Inc (MRNA)

Days of sales outstanding (DSO)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Receivables turnover		6.63	4.41	17.61	10.18	11.88	7.72	8.23	6.82	5.69	3.70	3.39	0.85	0.57	1.23	2.60	3.35	4.93	5.35
DSO	days	55.09	82.74	20.73	35.85	30.73	47.27	44.33	53.51	64.12	98.69	107.70	429.93	636.49	297.44	140.59	109.08	73.98	68.28

December 31, 2023 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 6.63
= 55.09

To analyze Moderna Inc's Days of Sales Outstanding (DSO) based on the provided data, we observe fluctuations in the collection period over the past eight quarters.

In Q1 2023, the DSO was 34.54 days, indicating that on average, it took the company about 34.54 days to collect payments for sales made during that quarter. This was a noticeable decrease compared to the previous quarter, Q4 2022, where the DSO was 35.07 days.

The lowest DSO was observed in Q2 2023 at 12.30 days, suggesting that the company was able to collect payments more efficiently during that period. However, this significant decrease was followed by a substantial increase in Q3 2023, with the DSO rising to 79.47 days, reflecting a potential delay in receivables collection during that quarter.

Overall, Moderna Inc's DSO has shown variability over the past eight quarters, indicating fluctuations in the company's accounts receivable collection efficiency. Further analysis and comparison with industry benchmarks may provide insights into the company's credit policies, customer payment behavior, and overall financial performance.